chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Felt totally fine before flu shot was administered. Within 24 hrs. 10/7/18 Eye-lid swelled up. Was red, irritated and had some mucus in the eye as well. Went to urgent care and was prescribed antibiotics for 7 days. Diagnosed-conjunctivitis. 10/8/18 - Had 100.4 temp. all day. Felt very weak, sore throat, chills, slight cough. Very bad headache, stuffy nose, ear ache and felt very dizzy (had a hard time standing up.) Couldn't take feeling like this all day; so went to the ER at 11:30pm. Was administered IV for dehydration (fluids) and TYLENOL for severe headache. Upon discharged at ER, received an Rx for 600mg. Ibuprofen and ZOFRAN 4mg. for nausea (said it was viral). 10/9/18 - still was not feeling any better. Went to Primary physician. Was prescribed antibiotics. Amoxicillin 875mg. for 7 days. Diagnosed - sinus infection. Took strep test - came back negative. Physician said that I had something Viral that turned into bacterial due to a very low immune system. Missed work for entire week.
12/00; mononucleosis. 1/01; viral meningitis with non-epileptic seizures (lost 1 month of school). Seizures tapering to 1 occasionally and very mild. 6/1; After immunizations, seizures are back as in 1/01. Not recovered as of 6/14/01.
A little bit of headache; This is a spontaneous report received from a non-contactable consumer (patient). A patient of an unspecified age and gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: Not reported), via an unspecified route of administration on an unspecified date as 2nd dose, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient historical vaccine included first dose of BNT162B2 for COVID-19 immunization. It was reported that, the patient had the Pfizer's second shot yesterday and have a little bit of headache when woke up on an unspecified date in Feb2021. The outcome of event was reported as unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Itchy welts/bumps on various spots all over my right hand and on the bottom of my left foot/big toe. Tender, sore to touch, and very itchy at times. Increased in size over time and different spots were more or less itchy on different days. At the worst, I took 2 benadryl. It did not make them subside. I used hydrocortisone ointment daily. This event started 3/22 and ended 3/31
A non-serious spontaneous report of administration of FLUMIST to a pregnant female was received from a pharmacist concerning a 16-year-old female. No medical or obstetrical history was reported. On 30-Sep-2009 a pregnant female received FLUMIST at a drive thru clinic, the vaccine administrator did not ask the patient if she was pregnant. There was no adverse event experienced to date. Treatment and reporter/sponsor causality assessments are not applicable. The reporter was asked to inform when the pregnancy has ended and also to inform if the patient experiences any adverse events during pregnancy.
Pain, redness, warmth, and swelling at injection site lasting for 3 days. Fever ranging from 99.0-102.0 lasting 24 hour Muscle, joint, and body aches lasting 36 hours (moderate pain would be dulled by use of Tylenol every 4-6 hours) Nausea lasted 24 hours  Symptoms started to develop about 6 hours after the injection and continued to worsen through the night and peaked the next morning, and slowing started to get better over the 36 hours
Modern a COVID-19 Vaccine EUA.  First 24 hours-  mild soreness not at injection  site but 2-3 inches below injection site.  Days 2, 3, 4  muscle fatigue  and sensation of unusually elevated heart rate during stenuous exercise significant enough for me to take ?breathing breaks? to allow my heart to slow - like enforced interval training.  Days 5, 6, 7, 8 no noticeable side effects.  Day 9 slightly stiff sensation and itching at injection site, no rash,  no swelling. Day 10 (today) itching at injection site significant enough for me to stretch in my sleep.  Injection site visably swollen, warmer to the touch than surrounding area,  no rash.
Client had first dose of Moderna for 6 mo - 5 years.   Came in at 4 week interval for second dose of same.   He was inadvertently given Pfizer for 6 mo to 4 years.   WRONG BRAND given.
I gave a booster to this pt the vial was in the cabinet I believe it was still a good to give because it was still in the cabinet later during the day I was told by the other LPN that it was only for 12 hours I was shocked and distraught.
Fever or Chills  Cough  Muscle or body aches  New loss of taste or smell  Congestion or running nose
Information has been received from an office manager, in physician's office, concerning an office nurse's child who on an unspecified date was vaccinated with VARIVAX (Merck), Lot # not reported. Office manager reported that the child came down with chicken pox after being vaccinated with VARIVAX (Merck). The patient sought medical attention. Follow-up information received from the physician's office indicated they do not know which patient the report is referring to. No further information is available.
A report has been received from a Physician via company rep concerning a child, male subject, who had been receiving nasal FLUMIST Quadrivalent, dose and frequency unknown. FLUMIST Quadrivalent started on an unknown date. The reporter informed that patient had breakthrough and tested positive for flu A and B. The outcome of the event of tested positive for flu A and B is unknown. The report was considered to be non-serious.
Extremely tired, chills, and body aches from 3 hours after the vaccine was given, lasting for 2 days. Took ibruprophen 300mg every 8 hours and slept when I was not working.
Pt received Td on 01/17/2001. Pt returned on 01/19/2001 for red and swollen injection site, and was given Benadryl. On 01/20/2001 pt went to ER complaining of pain and increased swelling and redness at injection site. He was sent home with a dose of Ceftriaxone. Later same day pt returned to ER and was admitted to the hospital. On 01/22/2001 pt was discharged with full resolution of cellulitis, and was given dicloxacillin. No other medications were being taken at the time of the vaccination and no underlying disease conditions were reported.
dose was administered after 12 hours of puncturing the vial; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose was administered after 12 hours of puncturing the vial) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (dose was administered after 12 hours of puncturing the vial). On 23-Jul-2021, EXPIRED PRODUCT ADMINISTERED (dose was administered after 12 hours of puncturing the vial) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Vial was stored on the refrigerator on Sunday 18July2021 in the Morning. The vial was punctured at 6 pm on 22-Jul-2021.  This was the first dose of the patient, and patient had no symptoms after the administration.   No concomitant medications were reported.  No treatment medications were reported.
Fever, swollen leg, excessive crying for prolonged periods of time. After the administration of Tylenol, he slept 14 hours.
had aches the next day; Initial information received on 19-Oct-2020 regarding an unsolicited valid non-serious social media case received from a non-healthcare professional (consumer) via Social Media.  This case involved a patient of an unknown demographic who had aches (pain), after receiving INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, had aches the next day. This was the first time that has happened. they got the senior dose. patient feel it was just their immune system letting was know it was working.  No relevant laboratory details were provided.  It was not reported if the patient received a corrective treatment.  Outcome was reported as unknown for the event pain.  There will be no information available on the batch number for this case.
Initial report received from literature on 28 December 2014. This case is linked to case number 2015SA000156, 2015SA000157 and 2015SA000159 (same literature report). The following is the verbatim for the article abstract: A number of medications have been associated with uveitis. This review highlights both well-established and recently reported systemic, topical, intraocular, and vaccine-associated causes of drug-induced uveitis, and assigns a quantitative score to each medication based upon criteria originally described. An unknown patient (age and gender was not reported), whose medical history and concomitant medications were not reported, had received a dose of INFLUENZA VACCINE (manufacturer- unknown, batch number, route, dose number and site of administration was not reported) on an unspecified date. On an unspecified date patient had experienced reactivation of acute retinal necrosis after vaccination. It was reported that the influenza vaccination has been implicated in the development of secondary uveitis in several case reports, including bilateral panuveitis, recurrent panuveitis and acute posterior multifocal placoid pigment epitheliopathy (APMPPE). Anterior uveitis can be controlled with topical corticosteroids and a cycloplegic/mydriatic agent, whereas posterior involvement may require systemic corticosteroids. Laboratory investigation and corrective treatment was not reported. At the time of reporting, patient outcome was unknown. Upon medical review, the case was considered as serious due to important medical event: reactivation of acute retinal necrosis (ARN). List of documents held by sender: none.
Patient reported aches of (hands, legs, head) that started on 9/19/2012 am and were resolved by 9/20/12 afternoon. Patient took acetaminophen for aches.
no adverse effects were reported; patient received improperly stored M-M-R II on 6/29/2020, after prior excursion on 6/25/2020; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions, allergies and concomitant medications were not provided.   On 29-JUN-2020, the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (albumin status: recombinant Human albumin (rHA)) lot # R030812, expiration date 24-OCT-2020 for prophylaxis (exact dose, dose #, route of administration were not provided). The vaccine was reconstituted with properly stored sterile diluent (MERCK STERILE DILUENT) lot # S038150, expiration date 07-AUG-2022. On 25-JUN-2020, the temperature excursion was above 47 degrees Fahrenheit (F) (46.6 F) for 6 minutes. There was no previous excursions reported. The digital data logger was involved.  On 19-JUL-2020, the next temperature excursions were: above 47 degrees F (56.8 F) for 2 hours and 37 minutes and below 36 degrees F (33.1 F) for 12 minutes. No adverse effects were reported.
An improperly stored vaccine was administered to 10 separate patients. No additional AE reported; An improperly stored vaccine was administered to 10 separate patients. No additional AE reported; This spontaneous report has been received from an office manager, concerning a 3-months-old patient of unknown gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, concurrent conditions, and previous drug reactions or allergies.  The Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB) lot number T042013 underwent a temperature excursion of 11.43 degrees Celsius (C) for a time frame of 4 hours and 45 minutes; no previous temperature excursion (product storage error).   Consequently, on 25-APR-2022 the patient was vaccinated with the inappropriate storage Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB) (lot number T042013 has been verified to be a valid lot, expiration date reported and stablished as 22-JUL-2023) as prophylaxis (formulation, strength, dose, vaccination scheme, route of administration and anatomical location were not provided) (product storage error). No additional adverse events (AE) reported (no adverse event).  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2205USA002988: US-009507513-2205USA003266: US-009507513-2205USA003043: US-009507513-2205USA002913: US-009507513-2205USA002848: US-009507513-2205USA003131: US-009507513-2205USA003118: US-009507513-2205USA002951: US-009507513-2205USA003121:
ER Triage Note   patient a 59 year old FEMALE presents to Emergency   Department on 01/07/22 09:02.       Tetanus status: Last Tdap: Oct 20, 2020      LMP:    Chief Complaint: Visit CC: cough.  {Date and Time of Arrival: 07-Jan-2022 22:06 patient is a 59 old FEMALE who is being admitted to care unit for observation due to diagnosis of   PNA, hypoxia   patient is being admitted to HOSPITAL  patient a 59 year old FEMALE currently  on care unit was admitted on JAN 8,2022 09:30.The patient is being discharged 09-Jan-2022by staff   LOCAL TITLE: CASE MANAGEMENT DISCHARGE FOLLOW UP                 STANDARD TITLE: CASE MANAGER NOTE                                DATE OF NOTE: JAN 10, 2022@15:56:44  ENTRY DATE: JAN 10, 2022@15:56:44             AUTHOR:        EXP COSIGNER:                                 URGENCY:                            STATUS: COMPLETED                           SUBJECT: followup                                                           Patient discharged from care unit following pneumonia and hypoxia
Rapid development of paresis in the arms and legs. Diagnosis of Guillain Barre. Admitted to hospital and treated with 5 day course of IV igG. Developed bifacial paresis. Physical, occupational,and speech therapy initiated.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 21-FEB-2019, the patient was vaccinated with one improperly stored dose of VARIVAX, lot # R023502, expiry date: 16-AUG-2020 (exact dose, route of administration and anatomical location were not provided) for prophylaxis. The administered dose of vaccine was reconstituted with improperly stored sterile diluent, lot # R034106, expiry date: 22-JUN-2021 (dose, route of administration, anatomical location and indication were not provided). The reporter did not know temperature and time frame of excursion. There was no previous temperature excursion. It was not reported if digital data logger was involved. No adverse effects were reported. This is one of 4 reports received from the same reporter. Sender's Comments: US-009507513-1903USA005458: US-009507513-1903USA005457: US-009507513-1902USA010800.
This spontaneous report as received from a healthcare worker refers to a patient of unknown age. On an unknown date the patient was vaccinated with PNEUMOVAX23 (injection, lot #, dose/frequency, duration were unspecified) via the intradermal route. The patient currently reports no adverse effects. The outcome was unknown. Follow up information has been received from a Certified Medical Assistant. It was reported that a male patient with currently 28 years old had a pertinent medical history of seasonal allergies and allergy to penicillin. Also it was reported that on 10-JUL-2013 the patient developed a localized reaction that resolved in 2 days, on 12-JUL-2013. Additional information is not expected.
This spontaneous report as received from a Medical Assistant via Pfizer refers to a 66 year old male patient. The pertinent medical history was not provided. The patient's concurrent conditions included blood pressure management. On 15-JUN-2016 the patient was vaccinated with PREVNAR 13 0.5 ml, intramuscularly in the right deltoid muscle, instead of PNEUMOVAX 23. Concomitant therapies included lisinopril (manufacturer unknown) and unspecified multivitamins. Additional information has been requested.
After the second dose, the tingling went up to her shoulder to the back of her neck; She has tingling and numbing that goes off and on all day and night in the left side of her neck and shoulder.; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (After the second dose, the tingling went up to her shoulder to the back of her neck) and HYPOAESTHESIA (She has tingling and numbing that goes off and on all day and night in the left side of her neck and shoulder.) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026B21A and 029A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PARAESTHESIA (After the second dose, the tingling went up to her shoulder to the back of her neck) and HYPOAESTHESIA (She has tingling and numbing that goes off and on all day and night in the left side of her neck and shoulder.). At the time of the report, PARAESTHESIA (After the second dose, the tingling went up to her shoulder to the back of her neck) and HYPOAESTHESIA (She has tingling and numbing that goes off and on all day and night in the left side of her neck and shoulder.) outcome was unknown.            Concomitant medications were not provided.  Treatment information was not provided.   This case was linked to MOD-2021-318602 (Patient Link).
Initial unsolicited report received consumer on 4 May 2015. A female patient, who had medical history of Formaldehyde allergy and concomitant medications were not reported, received a dose of ADACEL (batch number -C4714AA, route of administration was not reported) on 23 April 2015. The patient has no illness at the time of vaccination. On 23 April 2015, few hours after vaccination, the patient experienced right upper arm bruising, soreness, hard area at injection site and hot to touch area at injection site. Patient also stated that for next several days she continued with right upper arm bruising, arm soreness, arm stiffness and also had headache, diarrhea, vomiting and all over body soreness. Laboratory investigations and corrective treatments were not reported. On an unspecified date, the patient recovered from the events body soreness, headache, diarrhea, and vomiting resolved but was still persisting with upper arm bruising, soreness, stiffness. As of 5 April 2015, the patient had not recovered from all the events. Documents held by sender: none. Follow-up report received from a physician on 22 June 2015. A 46 year old female patient had received 0.5 ml second intramuscular dose of ADACEL. On an unspecified date the patient had received first dose of ADACEL. List of documents held by sender: none.
Information has been received from a health professional concerning an 11 year old patient who was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). On 26-APR-2007, the patient was diagnosed with chickenpox. Medical attention was sought. The patient's outcome was unknown. No product quality complaint was involved. This is one of several from the same source. Further information has been requested.
Information has been received from a pharmacist via a company representative referring to a male patient of unknown age. The patient's medical history, concomitant therapy and concurrent condition were unknown. On an unknown date, the patient was vaccinated with ZOSTAVAX (strength, dose, frequency, route, lot number and expiration date were unknown). On an unknown date, the patient experienced shingles. The outcome of the event was unknown. The causal relationship between ZOSTAVAX and the event was unknown. Additional information is not expected as the pharmacist does not want to be contacted for follow up.
In the later afternoon of 10/19 patient's mother reports a few red dot like rash points on her face.  10/20 am she woke up with same rash over arms, legs and trunk.  By 10/21 am pin point rash in numbers mother reports being "too many to count".  Rash began decreasing in appearance by afternoon of 10/21, disappeared by 10/22 am.  Mother did not seek visit to doctor as instructed by Health Department staff due to regular MD not willing to see patient due to outstanding balance on account.  Health Department staff recommended urgent care visit and mother had agreed verbally on 10/21 am but did not follow through.
Patient reported reactivation of cerebral balsy with doctor 10 days after getting the shot on 11/09/2019. Talked to both doctor and patient, patient reported doing better today 12/05/2019
patient stated that he took the vaccine on 3/24/21 and a few days later is when he started to experience ringing in the ears. He stated he thought he slept wrong on his neck and maybe the ringing was due to that. He doesn't c/o any other symptoms besides trouble sleeping and hearing (a high pitched sound). Patient stated he's tried tylenol and ibuprofen and its not helping.
"Giving patient influenza vaccine. During administration, needle penetrated thigh and when plunger was pushed, vaccine sprayed out sideways through unseen whole plastic hub. Sprayed on mother. Site bandaged per routine. No visible break or hole in syringe yet leak evident between hub and syringe where needle is screwed in. Only the second syringe administered in this box lot# UT6647JA Sanofi." This reporter followed up with the RN who wrote the above statement and she said that no other vaccines in that lot had issues.
symptoms began appearing about 2.5 hours after injection.  moderate dizziness (fell 4-5 times - like being real tipsy, had to adjust how I moved); mild to moderate headache. 80% resolved after 36 hours. moderate stiffness and general muscle/joint aches and pain; mild chills. Resolved after 4 days. injection site soreness and swelling. Resolved after 8 days.
Pain throughout body, fatigue serious enough to send me to bed but also to prevent sleep. Even when lying perfectly still I experienced nerve pain in my elbow that I liken to jolts of electricity. After going to bed at 8 pm but remaining sleepless I arose at 1 am and took 400 mg of Ibuprofin. Pain lessened enough to allow fitful, interrupted  sleep. I remain in significant discomfort.
Information has been received from a medical assistant concerning a female patient who was vaccinated SC with a dose of pneumococcal vaccine 23 polyvalent (lot # 641531/1352L). Subsequently, the patient developed rash, edema and fever. Unspecified medical attention was sought. Additional information has been requested.